Aprotinin for acute respiratory distress syndrome
Part of Lungs & breathing clinical trials.
This trial tests a drug called aprotinin for people with moderate to severe ARDS who are on a breathing machine. The goal is to see if it helps treat the lung injury.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have moderate or severe ARDS as defined by your doctor.
- You must be on a breathing machine (intubated and ventilated).
- You must be 18 years or older.
- The first dose of the study drug must be given within 48 hours of your ARDS diagnosis.
- Women who can have children must have a negative pregnancy test and use effective birth control during the study and for 30 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This trial observes the symptoms, treatments, and recovery of patients with acute respiratory distress syndrome (ARDS), a serious lung condition. It aims to learn more about how different types of breathing support affect outcomes.
This trial tests if bevacizumab can help people with ARDS (a serious lung condition) breathe better. It is for patients with mild, moderate, or severe ARDS who are already in the hospital.
This study tests an experimental drug (STSA-1002) for people with severe breathing problems caused by a viral infection. It aims to see if the drug can help improve oxygen levels and reduce the need for a breathing machine.
This trial tests a new medicine called paridiprubart to see if it can help people with moderate or severe acute respiratory distress syndrome (ARDS), a serious lung condition. It may be an option if you have low oxygen levels and no known allergy to the drug.
This trial looks at how the immune system might cause severe breathing problems (ARDS). It may help doctors understand what happens in the lungs during this condition and find better ways to treat it.
Hear when a new Acute Respiratory Distress Syndrome (ARDS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.